The clinical trial landscape is undergoing a seismic shift. As the volume and complexity of trial data surge, traditional methods of managing and analyzing this information are proving insufficient, reactive, and costly. Fragmented datasets, manual reporting, and slow decision-making processes increase trial timelines and costs, reducing the probability of success.
At OmniScience, we are enabling biotech and pharma teams to transform clinical development by moving beyond traditional analytics to real-time, automated intelligence
Recent advances in generative AI (genAI) and agentic AI have unlocked new possibilities that were previously unimaginable. To unlock the value of genAI in clinical trial operations, applications require additional sophistication and regulatory considerations. OmniScience has created an agentic system specifically for clinical development to address core industry challenges, such as:
→ Unifying fragmented datasets to eliminate data silos
→ Enhancing data quality and integrity
→ Delivering actionable insights in real-time to accelerate trial timelines
→ Empowering teams with AI-driven next best action recommendations
At the heart of this transformation is Vivo, the world’s first genAI-powered clinical trial control tower - more than just a data aggregation tool, Vivo acts as an AI-driven colleague, reducing manual effort in key areas up to 60-70% by:
→ Providing real-time insights across clinical, operational, and safety
→ Predicting trial risks and trends before they escalate
→ Eliminating the need for spreadsheets, SQL queries, and manual reporting
→ Using agentic AI to provide explainable insights
85% of clinical trials face delays, and nearly 20% of total study costs - adding up to millions per trial - are spent on tasks that can be largely automated with AI. With rising R&D costs and complexity, the industry can no longer afford manual, error-prone processes.
GenAI represents an inflection point for clinical trials, offering a path to greater efficiency, faster timelines, and better patient outcomes. But to realize its full potential, it must be built with domain-specific expertise, regulatory alignment, and explainability - all of which are embedded into OmniScience’s AI architecture.
To dive deeper into how Vivo is redefining clinical development, download our latest whitepaper, A New Era of Clinical Development Reasoning: Generative AI’s Transformative Role in Clinical Trial Operations. Download the Whitepaper here.
Want to discuss how AI-powered clinical development can drive success for your team? Let’s connect. OmniScience is partnering with leading biotech and pharma organizations to bring the future of clinical trials to life - today.
